Natural History of Patients With PH3 and a History of Stone Events (PHYOX-OBX)

• ClinicalTrials.gov Identifier: NCT04542590
• Recruitment Status: Recruiting
• First Posted: September 9, 2020
• Last Update Posted: November 18, 2021
• Sponsor: Dicerna Pharmaceuticals, Inc.
• Information provided by (Responsible Party): Dicerna Pharmaceuticals, Inc.

Tracking Information

• First Submitted Date: August 20, 2020
• First Posted Date: September 9, 2020
• Last Update Posted Date: November 18, 2021
• Actual Study Start Date: September 9, 2021
• Estimated Primary Completion Date: February 28, 2024 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: September 2, 2020)

• Collect stone formation data in PH3 patients [ Time Frame: Assess participants' stone formation rates over the course of 2 years ]
  Collect data on the rate of new stone formation in PH3 patients of at least 2 years of age
• Assess relationship between urine oxalate (Uox) levels and stone formations in PH3 patients [ Time Frame: Measure participants' Uox levels over the course of 2 years ]
  Explore the potential relationship between Uox levels and new stone formation in patients (≥ 2 years of age) with genetically confirmed PH3 and relatively intact renal function
• Collect data on the degree of nephrocalcinosis in PH3 patients [ Time Frame: Assess the change in nephrocalcinosis grade over the course of 2 years ]
  Collect data on the degree of nephrocalcinosis in PH3 patients of at least 2 years of age

• Original Primary Outcome Measures: Same as current
• Current Secondary Outcome Measures: Not Provided
• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Natural History of Patients With PH3 and a History of Stone Events
• Official Title: A Natural History Study of Patients With Genetically Confirmed Primary Hyperoxaluria Type 3 and, as Applicable Per Age, a History of Stone Events
• Brief Summary: This is a natural history study of adults, adolescents, and children (starting at birth) with genetically confirmed primary hyperoxaluria type 3 (PH3) who have a history of stone events during the last 3 years and/or the presence of pre existing stones detected by renal ultrasound at screening.

Detailed Description

The relationship between the level of Uox and the incidence of kidney stones and/or nephrocalcinosis in patients with PH3 has not been established. The goal of this study is to record 24-hour Uox levels and the incidence of new stone formation and/or the degree of nephrocalcinosis in patients with PH3 over time.

Potential participants are screened over an up-to-7 week period according to the eligibility criteria and will then be followed every 6 months over an up-to-2-year period to determine the annualized new stone formation rate (number of new stones being formed per year) and the change in the degree of nephrocalcinosis (if applicable).

New stone formation is defined as occurrence of any of the following:

• Spontaneous stone passage in the absence of pre-existing stones
• Stone passage occurring without change in the number of pre-existing stones detected by renal ultrasound
• Appearance of new stones on renal ultrasound or 100% or more growth of a pre-existing stone (estimated area)
• Surgical removal of newly formed stones Note: Spontaneous passage or surgical removal of pre-existing stones does not meet the criteria for new stone formation.

This is a non-interventional study that will last up to 2 years.

• Study Type: Observational [Patient Registry]
• Study Design: Observational Model: Cohort; Time Perspective: Prospective
• Target Follow-Up Duration: 2 Years
• Biospecimen: Not Provided
• Sampling Method: Non-Probability Sample
• Study Population: This is a natural history study in adults, adolescents, and children (starting from birth) with genetically confirmed PH3 who have a history of stone events during the last 3 years and/or the presence of preexisting stones detected by renal ultrasounds at Screening, and an eGFR > 30 mL/min/1.73 m2 or serum creatinine below the 97th percentile for patients younger than 12 months old.
• Condition: Primary Hyperoxaluria Type 3
• Intervention: Not Provided
• Study Groups/Cohorts: Not Provided
• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: May 13, 2021): 30
• Original Estimated Enrollment (submitted: September 2, 2020): 20
• Estimated Study Completion Date: February 28, 2024
• Estimated Primary Completion Date: February 28, 2024 (Final data collection date for primary outcome measure)

Eligibility Criteria

Key inclusion criteria

• Genetically confirmed PH3
• For participants at least 2 years of age, history of stone events (defined as presence of calcifications in the urinary tract and/or kidney, their relative location, and the number and size of stones) during the last 3 years and/or presence of pre-existing stones detected by renal ultrasound at Screening

• Uox ≥ 0.7 mmol/24 hours (adjusted per 1.73 m2 BSA in participants < 18 years of age) OR if not able to collect 24-hour urine, average spot Uox to creatinine ratio at Screening above the 95th percentile for age:

  • > 220 mmol/mol in participants < 6 months
  • > 170 mmol/mol in participants from 6 months to < 12 months
  • > 130 mmol/mol in participants 12 months to < 2 years
  • > 100 mmol/mol in participants from 2 to < 3 years and
  • > 80 mmol/mol in participants from 3 to 5 years
• eGFR at Screening ≥ 30 mL/min or for infants aged less than 12 months, serum creatinine below the 97th percentile of a healthy population

Key Exclusion Criteria:

• Prior or planned liver transplant within study period
• Currently receiving dialysis or anticipating dialysis during study period
• Unwillingness to comply with study procedures

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 2 Years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Medical Info; 617-621-8097; medicalinfo@dicerna.com

• Listed Location Countries: Canada, France, Germany, Lebanon, Poland, United Kingdom, United States

Administrative Information

• NCT Number: NCT04542590
• Other Study ID Numbers: DCR-PHXC-502
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Dicerna Pharmaceuticals, Inc.
• Original Responsible Party: Same as current
• Current Study Sponsor: Dicerna Pharmaceuticals, Inc.
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Alexandra Haagensen, MD, MBA; Dicerna Pharmaceuticals, Inc.

• PRS Account: Dicerna Pharmaceuticals, Inc.
• Verification Date: November 2021